Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Hyeon Woong Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7633-2373; OpenAlex author ID A5038314704. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2022: 1 paper · 2023: 4 papers · 2024: 1 paper · 2025: 3 papers

Papers 9

  1. SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. Co-author DOI 10.1038/s12276-025-01596-w↗
  2. The FOXP1-ABCG2 axis promotes the proliferation of cancer stem cells and induces chemoresistance in pancreatic cancer. Co-author DOI 10.1038/s41417-025-00896-7↗
  3. SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1038/s41419-025-07476-5↗
  4. Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2. Co-author DOI 10.32604/or.2024.044029↗
  5. The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC. Co-author DOI 10.1007/s00109-023-02369-6↗
  6. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin … Co-author DOI 10.1080/15384047.2023.2272334↗
  7. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/cells12202509↗
  8. CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer. Co-author DOI 10.3390/ijms241612993↗
  9. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. First author DOI 10.3389/fphar.2022.934746↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joon Seong Park · 8 shared papers, 2022–2025 · strength 1.56
  2. Woosol Chris Hong · 6 shared papers, 2022–2025 · strength 1.16
  3. Hyung Sun Kim · 5 shared papers, 2022–2024 · strength 0.89
  4. Myeong‐Jin Kim · 5 shared papers, 2022–2023 · strength 0.85
  5. Da Eun Lee · 4 shared papers, 2022–2024 · strength 0.73
  6. Wooil Kwon · 3 shared papers, 2025 · strength 0.73
  7. Jin‐Young Jang · 2 shared papers, 2025 · strength 0.48
  8. Hye‐Sol Jung · 2 shared papers, 2025 · strength 0.48
  9. Minsoo Kim · 2 shared papers, 2025 · strength 0.48
  10. Yun Sun Lee · 2 shared papers, 2023 · strength 0.34
  11. Joon Seong Park · 1 shared paper, 2025 · strength 0.25
  12. Won‐Gun Yun · 1 shared paper, 2025 · strength 0.25
  13. Jongman Yoo · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.